<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ACTICLATE- doxycycline hyclate tablet, coated </strong><br>Aqua Pharmaceuticals<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use ACTICLATE<span class="Sup">™</span>  safely and effectively.  See full prescribing information for ACTICLATE<span class="Sup">™</span>.
			<br>ACTICLATE<span class="Sup">™</span> (doxycycline hyclate USP) Tablets for oral use
			<br>Initial U.S. Approval:  1967
		</span></div>
<div></div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta"><br>ACTICLATE<span class="Sup">™</span> is a tetracycline-class antimicrobial indicated for: </p>
<ul>
<li>Rickettsial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<a href="#AB00101">1.1</a>)</li>
<li>Sexually transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<a href="#AB00102">1.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> (<a href="#AB00103">1.3</a>)</li>
<li>Specific <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> (<a href="#AB00104">1.4</a>)</li>
<li>Ophthalmic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<a href="#AB00105">1.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span>, including inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure) (<a href="#AB00106">1.6</a>)</li>
<li>Alternative treatment for selected <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> when penicillin is contraindicated (<a href="#AB00107">1.7</a>)</li>
<li>Adjunctive therapy in acute intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> and severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> (<a href="#AB00108">1.8</a>)</li>
<li>Prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> (<a href="#AB00109">1.9</a>)<br>
</li>
</ul>
<p class="Highlighta">To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate and other antimicrobial drugs, ACTICLATE Tablets should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.  (<a href="#AB00100">1</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Adults:  the usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours) followed by a maintenance dose of 100 mg daily.  In the management of more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (particularly chronic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the urinary tract), 100 mg every 12 hours is recommended.  (<a href="#AB00201">2.1</a>)</li>
<li>For children above eight years of age:  The recommended dosage schedule for children weighing 45 kg or less is 4.4 mg per kg of body weight divided into two doses on the first day of treatment, followed by 2.2 mg per kg of body weight given as a single daily dose or divided into two doses on subsequent days.  For more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, up to 4.4 mg per kg of body weight may be used.  For children over 45 kg, the usual adult dose should be used.  (<a href="#AB00201">2.1</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets, 75 mg and 150 mg (functionally scored)  (<a href="#AB00300">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Doxycycline is contraindicated in persons who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the tetracyclines.  (<a href="#AB00400">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>The use of drugs of the tetracycline-class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown).  (<a href="#AB00501">5.1</a>)</li>
<li>
<span class="Italics">Clostridium difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>: Evaluate patients if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs.  (<a href="#AB00502">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines.  Limit sun exposure.  (<a href="#AB00503">5.3</a>)</li>
<li>Overgrowth of non-susceptible organisms, including fungi, may occur.  Reevaluate therapy if <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs.  (<a href="#AB00504">5.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Adverse reactions observed in patients receiving tetracyclines include <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>.  (<a href="#AB00600">6</a>)<br><br> </p>
<p class="Bold Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Aqua Pharmaceuticals at 1-866-665-2782, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage (<a href="#AB00701">7.1</a>)</li>
<li>Avoid coadministration of tetracyclines with penicillin (<a href="#AB00702">7.2</a>)</li>
<li>Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron-containing preparations (<a href="#AB00703">7.3</a>)</li>
<li>Concurrent use of tetracycline may render oral contraceptives less effective (<a href="#AB00704">7.4</a>)</li>
<li>Barbiturates, carbamazepine and phenytoin decrease the half-life of doxycycline (<a href="#AB00705">7.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Tetracycline-class drugs can cause fetal harm when administered to a pregnant woman, but data for doxycycline are limited. (<a href="#AB00506">5.6</a>, <a href="#AB00801">8.1</a>)</li>
<li>Tetracyclines are excreted in human milk; however, the extent of absorption of doxycycline in the breastfed infant is not known.  Doxycycline use during nursing should be avoided if possible.  (<a href="#AB00803">8.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 7/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Rickettsial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2	Sexually Transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3	<span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory Tract Infections</span></a></h2>
<h2><a href="#section-1.4" class="toc">1.4	Specific <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial Infections</span></a></h2>
<h2><a href="#section-1.5" class="toc">1.5	Ophthalmic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-1.6" class="toc">1.6	<span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> Including Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (Post-Exposure)</a></h2>
<h2><a href="#section-1.7" class="toc">1.7	Alternative Treatment for Selected <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> when Penicillin is Contraindicated</a></h2>
<h2><a href="#section-1.8" class="toc">1.8	Adjunctive Therapy for Acute Intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">Amebiasis</span> and Severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></a></h2>
<h2><a href="#section-1.9" class="toc">1.9	Prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span></a></h2>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Usual Dosage and Administration</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (Post-Exposure)</a></h2>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Tooth Development</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	<span class="Italics">Clostridium difficile</span> Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3	<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4	<span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">Superinfection</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	<span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Intracranial Hypertension</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Skeletal Development</a></h2>
<h2><a href="#section-5.7" class="toc">5.7	Antianabolic Action</a></h2>
<h2><a href="#section-5.8" class="toc">5.8	<span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9	Development of Drug-Resistant Bacteria</a></h2>
<h2><a href="#section-5.10" class="toc">5.10	Laboratory Monitoring for Long-Term Therapy</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Anticoagulant Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Penicillin</a></h2>
<h2><a href="#section-7.3" class="toc">7.3	Antacids and Iron Preparations</a></h2>
<h2><a href="#section-7.4" class="toc">7.4	Oral Contraceptives</a></h2>
<h2><a href="#section-7.5" class="toc">7.5	Barbiturates and Anti-Epileptics</a></h2>
<h2><a href="#section-7.6" class="toc">7.6	Penthrane<span class="Sup">®</span></a></h2>
<h2><a href="#section-7.7" class="toc">7.7	Drug and Laboratory Test Interactions</a></h2>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5  Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3  Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4	Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">15  REFERENCES</a></h1>
<h1><a href="#section-14" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1	Instructions for Breaking the 150 mg Tablet</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="AB00100"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of ACTICLATE and other antibacterial drugs, ACTICLATE should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p>Doxycycline is a tetracycline-class antibacterial indicated in the following conditions or diseases:</p>
<div class="Section" data-sectionCode="34067-9">
<a name="AB00101"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Rickettsial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Rocky Mountain spotted <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, typhus <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and the typhus group, Q <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>,  rickettsial pox, and tick <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fevers</span> caused by <span class="Italics">Rickettsiae</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="AB00102"></a><a name="section-1.2"></a><p></p>
<h2>1.2	Sexually Transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Uncomplicated urethral, endocervical or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics">Chlamydia trachomatis</span>.</p>
<p>Nongonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> caused by <span class="Italics">Ureaplasma urealyticum</span>.</p>
<p>Lymphogranuloma venereum caused by <span class="Italics">Chlamydia trachomatis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="199726" conceptname="Granuloma inguinale">Granuloma inguinale</span> caused by <span class="Italics">Klebsiella granulomatis</span>.</p>
<p>Uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> caused by <span class="Italics">Neisseria gonorrhoeae</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="138973" conceptname="Chancroid">Chancroid</span> caused by <span class="Italics">Haemophilus ducreyi</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="AB00103"></a><a name="section-1.3"></a><p></p>
<h2>1.3	<span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory Tract Infections</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> caused by <span class="Italics">Mycoplasma pneumoniae</span>.</p>
<p>Psittacosis (ornithosis) caused by <span class="Italics">Chlamydophila psittaci</span>.</p>
<p>Because many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.</p>
<p>Doxycycline is indicated for treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by the following microorganisms, when bacteriological testing indicates appropriate susceptibility to the drug:</p>
<p><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> caused by <span class="Italics">Haemophilus influenzae</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> caused by <span class="Italics">Klebsiella</span> species.</p>
<p><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory infections</span> caused by <span class="Italics">Streptococcus pneumoniae</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="AB00104"></a><a name="section-1.4"></a><p></p>
<h2>1.4	Specific <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial Infections</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="440637" conceptname="Relapsing fever">Relapsing fever</span> due to <span class="Italics">Borrelia recurrentis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">Plague</span> due to <span class="Italics">Yersinia pestis</span>.</p>
<p>Tularemia due to <span class="Italics">Francisella tularensis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="198677" conceptname="Cholera">Cholera</span> caused by <span class="Italics">Vibrio cholerae</span>.</p>
<p>Campylobacter fetus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics">Campylobacter fetus.</span></p>
<p><span class="product-label-link" type="condition" conceptid="441497" conceptname="Brucellosis">Brucellosis</span> due to <span class="Italics">Brucella</span> species (in conjunction with streptomycin).</p>
<p>Bartonellosis due to <span class="Italics">Bartonella bacilliformis</span>.</p>
<p>Because many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.</p>
<p>Doxycycline is indicated for treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by the following gram-negative microorganisms, when bacteriological testing indicates appropriate susceptibility to the drug:</p>
<p><span class="Italics">Escherichia coli</span></p>
<p><span class="Italics">Enterobacter aerogenes</span></p>
<p><span class="Italics">Shigella</span> species</p>
<p><span class="Italics">Acinetobacter</span> species</p>
<p><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span> caused by <span class="Italics">Klebsiella</span> species.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="AB00105"></a><a name="section-1.5"></a><p></p>
<h2>1.5	Ophthalmic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Trachoma caused by <span class="Italics">Chlamydia trachomatis</span>, although the infectious agent is not always eliminated as judged by immunofluorescence.</p>
<p>Inclusion <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> caused by <span class="Italics">Chlamydia trachomatis</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="AB00106"></a><a name="section-1.6"></a><p></p>
<h2>1.6	<span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> Including Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (Post-Exposure)</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> due to <span class="Italics">Bacillus anthracis</span>, including inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized <span class="Italics">Bacillus anthracis</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="AB00107"></a><a name="section-1.7"></a><p></p>
<h2>1.7	Alternative Treatment for Selected <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> when Penicillin is Contraindicated</h2>
<p class="First">When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:</p>
<p><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> caused by <span class="Italics">Treponema pallidum</span>.</p>
<p>Yaws caused by <span class="Italics">Treponema pallidum </span>subspecies <span class="Italics">pertenue</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="438059" conceptname="Listeriosis">Listeriosis</span> due to <span class="Italics">Listeria monocytogenes</span>.</p>
<p>Vincent’s <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by <span class="Italics">Fusobacterium fusiforme</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="436020" conceptname="Actinomycotic infection">Actinomycosis</span> caused by <span class="Italics">Actinomyces israelii</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> caused by <span class="Italics">Clostridium</span> species.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="AB00108"></a><a name="section-1.8"></a><p></p>
<h2>1.8	Adjunctive Therapy for Acute Intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">Amebiasis</span> and Severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></h2>
<p class="First">In acute intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span>, doxycycline may be a useful adjunct to amebicides.  In severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, doxycycline may be useful adjunctive therapy.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="AB00109"></a><a name="section-1.9"></a><p></p>
<h2>1.9	Prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span></h2>
<p class="First">Doxycycline is indicated for the prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> due to <span class="Italics">Plasmodium falciparum</span> in short-term travelers (less than 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> [see <span class="Italics">Dosage and Administration</span> (<a href="#AB00202">2.2</a>) and <span class="Italics">Patient Counseling Information</span> (<a href="#AB01700">17</a>)].</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="AB00200"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="34068-7">
<a name="AB00201"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Usual Dosage and Administration</h2>
<p class="First">The usual dosage and frequency of administration of doxycycline differs from that of the other tetracyclines.  Exceeding the recommended dosage may result in an increased incidence of side effects.</p>
<p>Adults:  The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours), followed by a maintenance dose of 100 mg daily.  The maintenance dose may be administered as a single dose or as 50 mg every 12 hours.  In the management of more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (particularly chronic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the urinary tract), 100 mg every 12 hours is recommended.</p>
<p>For pediatric patients above eight years of age:  The recommended dosage schedule for children weighing 45 kg or less is 4.4 mg per kg of body weight divided into two doses on the first day of treatment, followed by 2.2 mg per kg of body weight given as a single daily dose or divided into two doses on subsequent days.  For more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, up to 4.4 mg per kg of body weight may be used.  For children over 45 kg, the usual adult dose should be used.</p>
<p>Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline-class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration [see <span class="Italics">Adverse Reactions</span> (<a href="#AB00601">6.1</a>)].</p>
<p>If <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span> occurs, doxycycline may be given with food or milk [see <span class="Italics">Clinical Pharmacology</span> (<a href="#AB01203">12.3</a>)].</p>
<p>When used in <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, therapy should be continued for 10 days.</p>
<p>Uncomplicated urethral, endocervical, or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by <span class="Italics">Chlamydia trachomatis</span>: 100 mg by mouth twice-a-day for 7 days. </p>
<p>Uncomplicated gonococcal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in adults (except anorectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in men):  100 mg, by mouth, twice-a-day for 7 days. As an alternate single visit dose, administer 300 mg stat followed in one hour by a second 300 mg dose.</p>
<p>Nongonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> (NGU) caused by <span class="Italics">C. trachomatis</span> and <span class="Italics">U. urealyticum</span>:  100 mg by mouth twice-a-day for 7 days.</p>
<p><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> – early:  Patients who are allergic to penicillin should be treated with doxycycline 100 mg by mouth twice-a-day for 2 weeks.</p>
<p><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> of more than one year’s duration:  Patients who are allergic to penicillin should be treated with doxycycline 100 mg by mouth twice-a-day for 4 weeks.</p>
<p>Acute epididymo-<span class="product-label-link" type="condition" conceptid="4171915" conceptname="Orchitis">orchitis</span> caused by <span class="Italics">N. gonorrhoeae</span>:  100 mg by mouth, twice-a-day for at least 10 days.</p>
<p>Acute epididymo-<span class="product-label-link" type="condition" conceptid="4171915" conceptname="Orchitis">orchitis</span> caused by <span class="Italics">C. trachomatis</span>:  100 mg, by mouth, twice-a-day for at least 10 days.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="AB00202"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span></h2>
<p class="First">For adults, the recommended dose is 100 mg daily.  For children over 8 years of age, the recommended dose is 2 mg per kg given once daily up to the adult dose.  Prophylaxis should begin 1 or 2 days before travel to the malarious area.  Prophylaxis should be continued daily during travel in the malarious area and for 4 weeks after the traveler leaves the malarious area.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="AB00203"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (Post-Exposure)</h2>
<p class="First">ADULTS:  100 mg, of doxycycline, by mouth, twice-a-day for 60 days.</p>
<p>CHILDREN:  weighing less than 45 kg, 2.2 mg per kg of body weight, by mouth, twice-a-day for 60 days.  Children weighing 45 kg or more should receive the adult dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="AB00300"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">ACTICLATE<span class="Sup">™</span> (doxycycline hyclate USP) Tablets, 75 mg are round, convex, light-teal, film-coated, tablets with "75" debossed on one side of the tablet and "AQ101" debossed on the other.</p>
<p>ACTICLATE<span class="Sup">™</span> (doxycycline hyclate USP) Tablets, 150 mg are oval-shaped, convex, mossy-green, film-coated tablets.  Each side of the functionally scored  tablet has two parallel score lines for splitting into 3 equal portions with "A" debossed on each portion of one side of the tablet, and no debossing on the other.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="AB00400"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<p class="First">The drug is contraindicated in persons who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the tetracyclines.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="AB00500"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="AB00501"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Tooth Development</h2>
<p class="First">The use of drugs of the tetracycline-class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown).  This adverse reaction is more common during long-term use of the drugs but it has been observed following repeated short-term courses.  <span class="product-label-link" type="condition" conceptid="4131814" conceptname="Enamel hypoplasia">Enamel hypoplasia</span> has also been reported.  Doxycycline should not be used in this age group, except for <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span>, including inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure), unless other drugs are not likely to be effective or are contraindicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AB00502"></a><a name="section-5.2"></a><p></p>
<h2>5.2	<span class="Italics">Clostridium difficile</span> Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First"><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including ACTICLATE, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.  Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD.  Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antibacterial therapy and may require colectomy.  CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibacterial use.  Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibacterial use not directed against <span class="Italics">C. difficile</span> may need to be discontinued.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AB00503"></a><a name="section-5.3"></a><p></p>
<h2>5.3	<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines.  Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">skin erythema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AB00504"></a><a name="section-5.4"></a><p></p>
<h2>5.4	<span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">Superinfection</span></h2>
<p class="First">As with other antibacterial preparations, use of ACTICLATE may result in overgrowth of non-susceptible organisms, including fungi.  If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, the antibacterial should be discontinued and appropriate therapy instituted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AB00505"></a><a name="section-5.5"></a><p></p>
<h2>5.5	<span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Intracranial Hypertension</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Intracranial hypertension</span> (IH, <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>) has been associated with the use of tetracyclines including ACTICLATE. Clinical manifestations of IH include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, and <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>; <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> can be found on fundoscopy. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. Concomitant use of isotretinoin and ACTICLATE should be avoided because isotretinoin is also known to cause <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>.</p>
<p>Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. If <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span> occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AB00506"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Skeletal Development</h2>
<p class="First">All tetracyclines form a stable calcium complex in any bone-forming tissue.  A decrease in fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg per kg every six hours.  This reaction was shown to be reversible when the drug was discontinued.</p>
<p>Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development).  Evidence of embryotoxicity also has been noted in animals treated early in pregnancy. Tetracycline-class drugs can cause fetal harm when administered to a pregnant woman, but data for doxycycline are limited. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AB00507"></a><a name="section-5.7"></a><p></p>
<h2>5.7	Antianabolic Action</h2>
<p class="First">The antianabolic action of the tetracyclines may cause an increase in BUN.  Studies to date indicate that this does not occur with the use of doxycycline in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AB00508"></a><a name="section-5.8"></a><p></p>
<h2>5.8	<span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span></h2>
<p class="First">Doxycycline offers substantial but not complete suppression of the asexual blood stages of <span class="Italics">Plasmodium</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.</p>
<p>Doxycycline does not suppress <span class="Italics">P. falciparum’s</span> sexual blood stage gametocytes.  Subjects completing this <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> regimen may still transmit the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to mosquitoes outside endemic areas.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AB00509"></a><a name="section-5.9"></a><p></p>
<h2>5.9	Development of Drug-Resistant Bacteria</h2>
<p class="First">Prescribing ACTICLATE in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AB05010"></a><a name="section-5.10"></a><p></p>
<h2>5.10	Laboratory Monitoring for Long-Term Therapy</h2>
<p class="First">In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal and hepatic studies should be performed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AB00600"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="34084-4">
<a name="AB00601"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of doxycycline hyclate tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>Due to oral doxycycline’s virtually complete absorption, side effects to the lower bowel, particularly <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, have been infrequent.  The following adverse reactions have been observed in patients receiving tetracyclines:</p>
<p><span class="Italics">Gastrointestinal</span>: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, and inflammatory lesions (with monilial overgrowth) in the anogenital region.  Hepatotoxicity has been reported.  These reactions have been caused by both the oral and parenteral administration of tetracyclines.  Instances of <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> and <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulcerations</span> have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline-class.  Most of these patients took medications immediately before going to bed [see <span class="Italics">Dosage and Administration</span> (<a href="#AB00201">2.1</a>)].</p>
<p><span class="Italics">Skin</span>:  Maculopapular and erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> have been reported.  <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> is discussed above  [see <span class="Italics">Warnings and Precautions</span> (<a href="#AB00503">5.3</a>)].</p>
<p><span class="Italics">Renal</span>: Rise in BUN has been reported and is apparently dose-related [see <span class="Italics">Warnings and Precautions</span> (<a href="#AB00507">5.7</a>)].</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span></span>: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="4101602" conceptname="Henoch-Schonlein purpura">anaphylactoid purpura</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, and exacerbation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
<p><span class="Italics">Blood</span>: <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> have been reported.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Intracranial Hypertension</span></span>: <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Intracranial hypertension</span> (IH, <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>) has been associated with the use of tetracyclines [see <span class="Italics">Warnings and Precautions</span> (<a href="#AB00505">5.5</a>)].</p>
<p><span class="Italics">Thyroid Gland Changes</span>:  When given over <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>, tetracyclines have been reported to produce brown-black microscopic discoloration of thyroid glands.  No abnormalities of thyroid function are known to occur.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="AB00700"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="34073-7">
<a name="AB00701"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Anticoagulant Drugs</h2>
<p class="First">Because tetracyclines have been shown to depress plasma <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="AB00702"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Penicillin</h2>
<p class="First">Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="AB00703"></a><a name="section-7.3"></a><p></p>
<h2>7.3	Antacids and Iron Preparations</h2>
<p class="First">Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="AB00704"></a><a name="section-7.4"></a><p></p>
<h2>7.4	Oral Contraceptives</h2>
<p class="First">Concurrent use of tetracycline may render oral contraceptives less effective.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="AB00705"></a><a name="section-7.5"></a><p></p>
<h2>7.5	Barbiturates and Anti-Epileptics</h2>
<p class="First">Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="AB00706"></a><a name="section-7.6"></a><p></p>
<h2>7.6	Penthrane<span class="Sup">®</span>
</h2>
<p class="First">The concurrent use of tetracycline and Penthrane<span class="Sup">®</span> (methoxyflurane) has been reported to result in fatal renal toxicity.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="AB00707"></a><a name="section-7.7"></a><p></p>
<h2>7.7	Drug and Laboratory Test Interactions</h2>
<p class="First">False elevations of urinary catecholamines may occur due to interference with the fluorescence test.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="AB00800"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="AB00801"></a><a name="section-8.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="Bold First">Teratogenic Effects.  Pregnancy Category D: [see <span class="Italics">Warnings and Precautions</span> (<a href="#AB00506">5.6</a>)]</p>
<p>There are no adequate and well-controlled studies on the use of doxycycline in pregnant women.  The vast majority of reported experience with doxycycline during human pregnancy is short-term, first trimester exposure.  There are no human data available to assess the effects of long-term therapy of doxycycline in pregnant women such as that proposed for the treatment of <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> exposure.  An expert review of published data on experiences with doxycycline use during pregnancy by TERIS - the Teratogen Information System - concluded that therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk (the quantity and quality of data were assessed as limited to fair), but the data are insufficient to state that there is no risk.<span class="Sup"><a href="#AB01500">1</a></span></p>
<p>A case-control study (18,515 mothers of infants with congenital anomalies and 32,804 mothers of infants with no congenital anomalies) shows a weak but marginally statistically significant association with total malformations and use of doxycycline anytime during pregnancy.  Sixty-three (0.19%) of the controls and 56 (0.30%) of the cases were treated with doxycycline.  This association was not seen when the analysis was confined to maternal treatment during the period of organogenesis (that is, in the second and third months of gestation), with the exception of a marginal relationship with <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defect</span> based on only two-exposed cases.<span class="Sup"><a href="#AB01500">2</a></span></p>
<p>A small prospective study of 81 pregnancies describes 43 pregnant women treated for 10 days with doxycycline during early first trimester.  All mothers reported their exposed infants were normal at 1 year of age.<span class="Sup"><a href="#AB01500">3</a></span></p>
<p>Nonteratogenic effects: [see <span class="Italics">Warnings and Precautions</span> (<a href="#AB00501">5.1</a>, <a href="#AB00506">5.6</a>)].</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="AB00803"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Tetracyclines are excreted in human milk, however, the extent of absorption of tetracyclines including doxycycline, by the breastfed infant is not known.  Short-term use by lactating women is not necessarily contraindicated.  The effects of prolonged exposure to doxycycline in breast milk are unknown<span class="Sup"><a href="#AB01500">4</a></span>.  Because of the potential for serious adverse reactions in nursing infants from doxycycline, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother [see <span class="Italics">Warnings and Precautions</span> (<a href="#AB00501">5.1</a>, <a href="#AB00506">5.6</a>)].</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="AB00804"></a><a name="section-8.3"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First">Because of the effects of drugs of the tetracycline-class on tooth development and growth, ACTICLATE should not be used in pediatric patients to the age of 8 years, unless the potential benefits are expected to outweigh the risks such as for <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span>, or when other drugs are not likely to be effective or are contraindicated [see <span class="Italics">Warnings and Precautions</span> (<a href="#AB00501">5.1</a>, <a href="#AB00506">5.6</a>) and <span class="Italics">Dosage and Administration</span> (<a href="#AB00201">2.1</a>, <a href="#AB00203">2.3</a>)].</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="AB00805"></a><a name="section-8.4"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First">Clinical studies of doxycycline hyclate tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</p>
<p>ACTICLATE Tablets, 75 mg contain 0.34 mg (0.0146 mEq) of sodium.
								<br>ACTICLATE Tablets, 150 mg contain 0.68 mg (0.0295 mEq) of sodium.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="AB01000"></a><a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First">In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures.  Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdosage.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="AB01100"></a><a name="section-10"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">ACTICLATE<span class="Sup">™</span> (doxycycline hyclate USP) Tablets contain doxycycline hyclate, a broad-spectrum antibacterial synthetically derived from oxytetracycline, in an immediate release formulation for oral administration.</p>
<p>The structural formula for doxycycline hyclate is:</p>
<p><img alt="Structural Formula for Doxycycline Hyclate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=115f1010-882f-11e3-baa7-0800200c9a66&amp;name=acticlate-01.jpg"></p>
<p>with a molecular formula of (C<span class="Sub">22</span>H<span class="Sub">24</span>N<span class="Sub">2</span>O<span class="Sub">8</span>, HCl)<span class="Sub">2</span>• C<span class="Sub">2</span>H<span class="Sub">6</span>O• H<span class="Sub">2</span>O and a molecular weight of  1025.87.</p>
<p>The chemical designation for doxycycline hyclate is:</p>
<p>4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate.</p>
<p>Doxycycline hyclate is a yellow crystalline powder soluble in water and in solutions of alkali hydroxides and carbonates.  Inactive ingredients in the tablet formulation are:  microcrystalline cellulose, sodium lauryl sulfate, croscarmellose sodium and magnesium stearate.  Film-coating contains:  polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, FD&amp;C Blue #1 (75 mg), FD&amp;C Yellow #6 (75 mg), FD&amp;C Blue #2 (150 mg) and yellow iron oxide (150 mg).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="AB01200"></a><a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="AB01201"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">Doxycycline is an antimicrobial drug [see <span class="Italics">Microbiology</span> (<a href="#AB01204">12.4</a>)].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="AB01203"></a><a name="section-11.2"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First">Doxycycline is virtually completely absorbed after oral administration.  Following administration of a single 300 mg dose to adult volunteers, average peak plasma doxycycline levels were 3.0 mcg per mL at 3 hours, decreasing to 1.18 mcg per mL at 24 hours.  The mean C<span class="Sub">max</span> and AUC <span class="Sub">0-∞</span> of doxycycline are 24% and 15% lower, respectively, following single dose administration of ACTICLATE, 150 mg tablets with a high fat meal (including milk) compared to fasted conditions. The clinical significance of these decreases is unknown.</p>
<p>Tetracyclines are concentrated in bile by the liver and excreted in the urine and feces at high concentrations and in a biologically active form.  Excretion of doxycycline by the kidney is about 40% per 72 hours in individuals with a creatinine clearance of about 75 mL per minute.  This percentage may <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> as low as 1% per 72 hours to 5% per 72 hours in individuals with a creatinine clearance below 10 mL per minute.</p>
<p>Studies have shown no significant difference in the serum half-life of doxycycline (range 18 to 22 hours) in individuals with normal and severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Hemodialysis does not alter the serum half-life.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AB01204"></a><a name="section-11.3"></a><p></p>
<h2>12.4	Microbiology</h2>
<p class="First Underline">Mechanism of Action</p>
<p>Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.  Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria.  Cross resistance with other tetracyclines is common.</p>
<p>Doxycycline has been shown to be active against most isolates of the following microorganisms, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the INDICATIONS AND USAGE section of the package insert for ACTICLATE [see <span class="Italics">Indications and Usage</span> (<a href="#AB00100">1</a>)].</p>
<p><span class="Bold">Gram-Negative Bacteria</span><br><span class="Italics">Acinetobacter</span> species
								<br><span class="Italics">Bartonella bacilliformis
								<br>Brucella</span> species
								<br><span class="Italics">Campylobacter fetus
								<br>Enterobacter aerogenes
								<br>Escherichia coli
								<br>Francisella tularensis
								<br>Haemophilus ducreyi
								<br>Haemophilus influenzae
								<br>Klebsiella granulomatis
								<br>Klebsiella</span> species
								<br><span class="Italics">Neisseria gonorrhoeae
								<br>Shigella</span> species
								<br><span class="Italics">Vibrio cholerae
								<br>Yersinia pestis</span></p>
<p><span class="Bold">Gram-Positive Bacteria</span><br><span class="Italics">Bacillus anthracis
								<br>Streptococcus pneumoniae</span></p>
<p><span class="Bold">Anaerobic Bacteria</span><br><span class="Italics">Clostridium</span> species
								<br><span class="Italics">Fusobacterium fusiforme
								<br>Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span></p>
<p><span class="Bold">Other Bacteria</span><br><span class="Italics">Nocardiae and other aerobic Actinomyces</span> species
								<br><span class="Italics">Borrelia recurrentis
								<br>Chlamydophila psittaci
								<br>Chlamydia trachomatis
								<br>Mycoplasma pneumoniae
								<br>Rickettsiae </span>species
								<br><span class="Italics">Treponema pallidum
								<br>Treponema pallidum</span> subspecies <span class="Italics">pertenue
								<br>Ureaplasma urealyticum</span></p>
<p><span class="Bold">Parasites</span><br><span class="Italics">Balantidium coli
								<br>Entamoeba</span> species
								<br><span class="Italics">Plasmodium falciparum<span class="Sup">*</span></span><br><span class="Sup">*</span>Doxycycline has been found to be active against the asexual erythrocytic forms of <span class="Italics">Plasmodium falciparum</span>, but not against the gametocytes of <span class="Italics">P. falciparum</span>.  The precise mechanism of action of the drug is not known.</p>
<p><span class="Underline">Susceptibility Testing Methods</span><br>When available, the clinical microbiology laboratory should provide the results of <span class="Italics">in vitro</span> susceptibility test results for antibacterial drugs used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens.  These reports should aid the physician in selecting the most effective antibacterial.</p>
<p><span class="Underline">Dilution techniques</span><br>Quantitative methods are used to determine antibacterial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs).  These MICs provide estimates of the susceptibility of bacteria to antibacterial compounds.  The MICs should be determined using a standardized test method <span class="Sup"><a href="#AB01500">5</a></span><span class="Sup">,</span><span class="Sup"><a href="#AB01500">6</a></span><span class="Sup">,</span><span class="Sup"><a href="#AB01500">7</a>,</span><span class="Sup"><a href="#AB01500">8</a>,</span><span class="Sup"><a href="#AB01500">9</a></span> (broth and/or agar).  The MIC values should be interpreted according to criteria provided in <a href="#Table1">Table 1</a>.</p>
<p><span class="Underline">Diffusion techniques</span><br>Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antibacterial compounds.  The zone size provides an estimate of the susceptibility of bacteria to antibacterial compounds.</p>
<p>The zone size should be determined using a standardized test method<span class="Sup"><a href="#AB01500">5</a></span><span class="Sup">,</span><span class="Sup"><a href="#AB01500">7</a></span><span class="Sup">,</span><span class="Sup"><a href="#AB01500">10</a></span>.  This procedure uses paper disks impregnated with 30 mcg doxycycline to test the susceptibility of microorganisms to doxycycline.  The disk diffusion interpretive criteria are provided in <a href="#Table1">Table 1</a>.</p>
<p><span class="Underline">Anaerobic Techniques</span><br>For anaerobic bacteria, the susceptibility to doxycycline can be determined by a standardized test method<span class="Sup"><a href="#AB01500">11</a></span>.  The MIC values obtained should be interpreted according to the criteria provided in <a href="#Table1">Table 1</a>.</p>
<a name="Table1"></a><table class="Noautorules" width="950">
<caption><span>Table 1:	Susceptibility Test Interpretive Criteria for Doxycycline and Tetracycline</span></caption>
<col align="left" width="25%">
<col align="center" width="8%">
<col align="center" width="8%">
<col align="center" width="8%">
<col align="center" width="8%">
<col align="center" width="8%">
<col align="center" width="8%">
<col align="center" width="8%">
<col align="center" width="8%">
<col align="center" width="8%">
<tfoot><tr><td align="left" colspan="10">
<p class="First"><span class="Sup">*</span>     Organisms susceptible to tetracycline are also considered susceptible to doxycycline.  However, some organisms that are intermediate or resistant to tetracycline may be susceptible to doxycycline.</p>
<p><span class="Sup">†</span>     The current absence of resistance isolates precludes defining any results other than "Susceptible".  If isolates yielding MIC results other than susceptible, they should be submitted to a reference laboratory for further testing.</p>
<p><span class="Sup">‡</span>     Gonococci with 30 mcg tetracycline disk zone diameters of less than 19 mm usually indicate a plasmid-mediated tetracycline resistant Neisseria gonorrhoeae isolate.  Resistance in these <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> should be confirmed by a dilution test (MIC ≥ 16 mcg per mL).</p>
</td></tr></tfoot>
<tbody class="Headless">
<tr>
<td class="Bold Lrule Rrule Toprule" align="left">
<br>Pathogen<span class="Sup">*</span>
</td>
<td class="Bold Botrule Lrule Rrule Toprule" align="center" colspan="3">Minimal Inhibitory Concentration <br>(mcg per mL)</td>
<td class="Bold Botrule Lrule Rrule Toprule" align="center" colspan="3">Zone Diameter (mm)</td>
<td class="Bold Botrule Lrule Rrule Toprule" align="center" colspan="3">Agar Dilution (mcg per mL)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"></td>
<td class="Bold Botrule Lrule Rrule" align="left">S</td>
<td class="Bold Botrule Lrule Rrule" align="left">I</td>
<td class="Bold Botrule Lrule Rrule" align="left">R</td>
<td class="Bold Botrule Lrule Rrule" align="left">S</td>
<td class="Bold Botrule Lrule Rrule" align="left">I</td>
<td class="Bold Botrule Lrule Rrule" align="left">R</td>
<td class="Bold Botrule Lrule Rrule" align="left">S</td>
<td class="Bold Botrule Lrule Rrule" align="left">I</td>
<td class="Bold Botrule Lrule Rrule" align="left">R</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Acinetobacter spp.</span><br>   Doxycycline<br>   Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≤4<br>≤4</td>
<td class="Botrule Lrule Rrule" align="left">
<br>8<br>8</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≥16<br>≥16</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≥13<br>≥15</td>
<td class="Botrule Lrule Rrule" align="left">
<br>10 - 12<br>12 - 14</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≤9<br>≤11</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Anaerobes<br>   Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≤4</td>
<td class="Botrule Lrule Rrule" align="left">
<br>8</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≥16</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Bacillus anthracis</span>†<br>   Doxycycline<br>   Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≤1<br>≤1</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Brucella species</span>†<br>   Doxycycline<br>   Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≤1<br>≤1</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Enterobacteriaceae</span><br>   Doxycycline<br>   Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br><br>≤4<br>≤4</td>
<td class="Botrule Lrule Rrule" align="left">
<br><br>8<br>8</td>
<td class="Botrule Lrule Rrule" align="left">
<br><br>≥16<br>≥16</td>
<td class="Botrule Lrule Rrule" align="left">
<br><br>≥14<br>≥15</td>
<td class="Botrule Lrule Rrule" align="left">
<br><br>11 - 13<br>12 - 14</td>
<td class="Botrule Lrule Rrule" align="left">
<br><br>≤10<br>≤11</td>
<td class="Botrule Lrule Rrule" align="left">
<br><br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br><br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br><br>-<br>-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Franciscella tularensis</span>†<br>   Doxycycline<br>   Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≤4<br>≤4</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Haemophilus influenzae</span><br>   Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≤2</td>
<td class="Botrule Lrule Rrule" align="left">
<br>4</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≥8</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≥29</td>
<td class="Botrule Lrule Rrule" align="left">
<br>26 - 28</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≤25</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Mycoplasma pneumoniae</span>†<br>   Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≤2</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Nocardiae</span> and other aerobic <span class="Italics">Actinomyces</span> species†<br>   Doxycycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br><br>≤1</td>
<td class="Botrule Lrule Rrule" align="left">
<br><br>2 - 4</td>
<td class="Botrule Lrule Rrule" align="left">
<br><br>≥8</td>
<td class="Botrule Lrule Rrule" align="left">
<br><br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br><br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br><br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br><br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br><br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br><br>-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Neisseria gonorrhoeae</span>‡<br>   Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≥38</td>
<td class="Botrule Lrule Rrule" align="left">
<br>31 - 37</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≤30</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≤0.25</td>
<td class="Botrule Lrule Rrule" align="left">
<br>0.5 - 1</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≥2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Streptococcus pneumoniae</span><br>   Doxycycline<br>   Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≤0.25<br>≤1</td>
<td class="Botrule Lrule Rrule" align="left">
<br>0.5<br>2</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≥1<br>≥4</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≥28<br>≥28</td>
<td class="Botrule Lrule Rrule" align="left">
<br>25 - 27<br>25 - 27</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≤24<br>≤24</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Vibrio cholerae</span><br>   Doxycycline<br>   Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≤4<br>≤4</td>
<td class="Botrule Lrule Rrule" align="left">
<br>8<br>8</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≥16<br>≥16</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Yersinia pestis</span><br>   Doxycycline<br>   Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≤4<br>≤4</td>
<td class="Botrule Lrule Rrule" align="left">
<br>8<br>8</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≥16<br>≥16</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Ureaplasma urealyticum</span><br>   Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≤1</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>≥2</td>
</tr>
</tbody>
</table>
<p>A report of <span class="Italics">Susceptible</span> (S) indicates that the antibacterial is likely to inhibit growth of the pathogen if the antibacterial compound reaches the concentrations at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site necessary to inhibit growth of the pathogen.  A report of <span class="Italics">Intermediate</span> (I) indicates that the result should be considered equivocal, and, if the bacteria is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated.  This category implies possible clinical applicability in body sites where the drug product is physiologically concentrated or in situations where high dosage of drug can be used.  This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation.  A report of <span class="Italics">Resistant</span> (R) indicates that the antibacterial is not likely to inhibit growth of the pathogen if the antibacterial compound reaches the concentrations usually achievable at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site; other therapy should be selected.</p>
<p><span class="Underline">Quality Control</span><br>Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test<span class="Sup"><a href="#AB01500">5</a></span><span class="Sup">,</span><span class="Sup"><a href="#AB01500">6</a></span><span class="Sup">,</span><span class="Sup"><a href="#AB01500">7</a></span><span class="Sup">,</span><span class="Sup"><a href="#AB01500">8</a></span><span class="Sup">,</span><span class="Sup"><a href="#AB01500">9</a></span><span class="Sup">,</span><span class="Sup"><a href="#AB01500">10</a></span><span class="Sup">,</span><span class="Sup"><a href="#AB01500">11</a></span>.  Standard doxycycline and tetracycline powders should provide the following range of MIC values noted in <a href="#Table2">Table 2</a>.  For the diffusion technique using the 30 mcg doxycycline disk the criteria noted in <a href="#Table2">Table 2</a> should be achieved.</p>
<a name="Table2"></a><table class="Noautorules" width="950">
<caption><span>Table 2:	Acceptable Quality Control Ranges for Susceptibility Testing for Doxycycline and Tetracycline</span></caption>
<col align="center" width="31%">
<col align="center" width="23%">
<col align="center" width="23%">
<col align="center" width="23%">
<tfoot><tr><td align="left" colspan="4">
<p class="First"><span class="Sup">a</span> ATCC is the American Type Culture Collection</p>
<p> </p>
<p><span class="Sup">b</span> For four-dilution ranges, results at the extremes of the acceptable ranges should be suspect. Verify with data from other control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.</p>
</td></tr></tfoot>
<tbody class="Headless">
<tr valign="middle">
<td class="Bold Botrule Lrule Rrule Toprule" align="left">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span></td>
<td class="Bold Botrule Lrule Rrule Toprule" align="center">Minimal Inhibitory<br>Concentration (mcg per mL)</td>
<td class="Bold Botrule Lrule Rrule Toprule" align="center">Zone Diameter (mm)</td>
<td class="Bold Botrule Lrule Rrule Toprule" align="center">Agar Dilution<span class="Sup">b</span> (mcg per mL)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Enterococcus faecalis</span> ATCC<span class="Sup">a</span>29212<br>    Doxycycline<br>    Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>2 - 8<br>8 - 32</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Escherichia coli</span> ATCC 25922<br>    Doxycycline<br>    Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>0.5 - 2<br>0.5 - 2</td>
<td class="Botrule Lrule Rrule" align="left">
<br>18 - 24<br>18 to 25</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Eubacterium  lentum</span> ATCC 43055<br>    Doxycycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>2 - 16</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Haemophilus influenzae</span> ATCC 49247<br>    Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>4 - 32</td>
<td class="Botrule Lrule Rrule" align="left">
<br>14 - 22</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Neisseria gonorrhoeae</span> ATCC 49226<br>    Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>30 - 42</td>
<td class="Botrule Lrule Rrule" align="left">
<br>0.25 - 1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Staphylococcus aureus</span> ATCC 25923<br>    Doxycycline<br>    Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>23 - 29<br>24 - 30</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Staphylococcus aureus</span> ATCC 29213<br>    Doxycycline<br>    Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>0.12 - 0.5<br>0.12 - 1</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Streptococcus pneumoniae</span> ATCC 49619<br>    Doxycycline<br>    Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>0.015 - 0.12<br>0.06 - 0.5</td>
<td class="Botrule Lrule Rrule" align="left">
<br>25 - 34<br>27 - 31</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Bacteroides fragilis</span> ATCC 25285<br>    Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>0.125 - 0.5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Bacteroides thetaiotaomicron</span> ATCC 29741<br>    Doxycycline<br>    Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>2 - 8<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-<br>8 - 32</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Mycoplasma hominis</span> ATCC 23114<br>    Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>0.12 - 1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Italics">Mycoplasma pneumoniae</span> ATCC 29342<br>    Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">
<br>0.06 - 5</td>
<td class="Botrule Lrule Rrule" align="left">
<br>-</td>
<td class="Botrule Lrule Rrule" align="left">
<br>0.06 - 5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">
<span class="Italics">Ureaplasma urealyticum</span> ATCC 33175</td>
<td class="Lrule Rrule" align="left"></td>
<td class="Lrule Rrule" align="left"></td>
<td class="Lrule Rrule" align="left"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">    Tetracycline</td>
<td class="Botrule Lrule Rrule" align="left">-</td>
<td class="Botrule Lrule Rrule" align="left">-</td>
<td class="Botrule Lrule Rrule" align="left">≥8</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="AB01300"></a><a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="AB01301"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals to evaluate carcinogenic potential of doxycycline have not been conducted.  However, there has been evidence of oncogenic activity in rats in studies with the related antibacterials, oxytetracycline (adrenal and pituitary tumors) and minocycline (<span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">thyroid tumors</span>).  Likewise, although mutagenicity studies of doxycycline have not been conducted, positive results in <span class="Italics">in vitro</span> mammalian cell assays have been reported for related antibacterials (tetracycline, oxytetracycline).</p>
<p>Doxycycline administered orally at dosage levels as high as 250 mg per kg per day had no apparent effect on the fertility of female rats.  Effect on male fertility has not been studied.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="AB01302"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Hyperpigmentation of the thyroid has been produced by members of the tetracycline-class in the following species: in rats by oxytetracycline, doxycycline, tetracycline PO<span class="Sub">4</span>, and methacycline; in minipigs by doxycycline, minocycline, tetracycline PO<span class="Sub">4</span>, and methacycline; in dogs by doxycycline and minocycline; in monkeys by minocycline.</p>
<p>Minocycline, tetracycline PO<span class="Sub">4</span>, methacycline, doxycycline, tetracycline base, oxytetracycline HCl, and tetracycline HCl, were goitrogenic in rats fed a low iodine diet.  This goitrogenic effect was accompanied by high radioactive iodine uptake.  Administration of minocycline also produced a large <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> with high radioiodine uptake in rats fed a relatively high iodine diet.</p>
<p>Treatment of various animal species with this class of drugs has also resulted in the induction of <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">thyroid hyperplasia</span> in the following: in rats and dogs (minocycline); in chickens (chlortetracycline); and in rats and mice (oxytetracycline).  Adrenal gland <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> has been observed in goats and rats treated with oxytetracycline.</p>
<p>Results of animal studies indicate that tetracyclines cross the placenta and are found in fetal tissues.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="AB01500"></a><a name="section-13"></a><p></p>
<h1>15  REFERENCES</h1>
<ol>
<li>Friedman JM, Polifka JE.  <span class="Italics">Teratogenic Effects of Drugs.  A Resource for Clinicians (TERIS).</span>  Baltimore, MD: The Johns Hopkins University Press: 2000: 149-195.</li>
<li>Cziezel AE and Rockenbauer M.  Teratogenic study of doxycycline.  Obstet Gynecol 1997; 89: 524-528.</li>
<li>Horne HW Jr. and Kundsin RB.  The role of mycoplasma among 81 consecutive pregnancies: a prospective study.  <span class="Italics">Int J Fertil</span> 1980; 25: 315-317.</li>
<li>Hale T.  <span class="Italics">Medications and Mothers Milk</span>.  9th edition.  Amarillo, TX: Pharmasoft Publishing 2000; 225-226.</li>
<li>Clinical and Laboratory Standards Institute (CLSI).  <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fourth Informational Supplement</span>, CLSI document M100-S24, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2014.</li>
<li>Clinical and Laboratory Standards Institute (CLSI).  <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – Ninth Edition</span>.  CLSI document M07-A9, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.</li>
<li>Clinical and Laboratory Standards Institute (CLSI).  <span class="Italics">Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline – Second Edition</span>.  CLSI document M45-A2, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2010.</li>
<li>Clinical and Laboratory Standards Institute (CLSI).  <span class="Italics">Methods for Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard – Second Edition</span>.  CLSI document M24-A2, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2011.</li>
<li>Clinical and Laboratory Standards Institute (CLSI).  <span class="Italics">Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas; Approved Guideline</span>.  CLSI document M43-A, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2011.</li>
<li>Clinical and Laboratory Standards Institute (CLSI).  <span class="Italics">Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard – Eleventh Edition</span>.  CLSI document M02-A11, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.</li>
<li>Clinical and Laboratory Standards Institute (CLSI).  <span class="Italics">Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard – Eighth Edition</span>.  CLSI document M11-A8, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="AB01600"></a><a name="section-14"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="Bold First">ACTICLATE<span class="Sup">™</span> (doxycycline hyclate USP) Tablets, 75 mg</p>
<p>Bottles of 60 tablets:	NDC 16110-501-01</p>
<p class="Bold">ACTICLATE<span class="Sup">™</span> (doxycycline hyclate USP) Tablets, 150 mg </p>
<p>Bottles of 60 tablets:	NDC 16110-502-01</p>
<p>Store at 20° to 25°C (68° to 77°F) excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].  Protect from light and moisture.  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="AB01700"></a><a name="section-15"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise patients taking doxycycline for <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> prophylaxis:</p>
<ul>
<li>that no present-day antimalarial agent, including doxycycline, guarantees protection against <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>.</li>
<li>to avoid being bitten by mosquitoes by using personal protective measures that help avoid contact with mosquitoes, especially from dusk to dawn (for example, staying in well-screened areas, using mosquito nets, covering the body with clothing, and using an effective insect repellent).</li>
<li>that doxycycline prophylaxis:
								<dl>
<dt>-</dt>
<dd>should begin 1 day to 2 days before travel to the malarious area,</dd>
<dt>-</dt>
<dd>should be continued daily while in the malarious area and after leaving the malarious area,</dd>
<dt>-</dt>
<dd>should be continued for 4 further weeks to avoid development of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> after returning from an endemic area,</dd>
<dt>-</dt>
<dd>should not exceed 4 months.</dd>
</dl>
</li>
</ul>
<p>Advise all patients taking doxycycline:</p>
<ul>
<li>to avoid excessive sunlight or artificial ultraviolet light while receiving doxycycline and to discontinue therapy if <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> (for example, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span>, etc.) occurs.  Sunscreen or sunblock should be considered [see <span class="Italics">Warnings and Precautions</span> (<a href="#AB00503">5.3</a>)].</li>
<li>to drink fluids liberally along with doxycycline to reduce the risk of esophageal irritation and ulceration [see <span class="Italics">Adverse Reactions</span> (<a href="#AB00601">6.1</a>)].</li>
<li>that the absorption of tetracyclines is reduced when taken with foods, especially those that contain calcium.  However, the absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk [see <span class="Italics">Drug Interactions</span> (<a href="#AB00703">7.3</a>)].</li>
<li>that the absorption of tetracyclines is reduced when taken with antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations [see <span class="Italics">Drug Interactions</span> (<a href="#AB00703">7.3</a>)].</li>
<li>that the use of doxycycline might increase the incidence of <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>.</li>
</ul>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibacterials which usually ends when the antibacterial is discontinued.  Sometimes after starting treatment with antibacterials, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of antibacterial.  If this occurs, patients should contact their physician as soon as possible.</p>
<p>Counsel patients that antibacterial drugs including ACTICLATE should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>.  They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (for example, the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>).  When ACTICLATE is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.  Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by ACTICLATE or other antibacterial drugs in the future.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="AB01701"></a><a name="section-15.1"></a><p></p>
<h2>17.1	Instructions for Breaking the 150 mg Tablet</h2>
<p class="First">Your doctor may find it necessary to adjust your dosage of ACTICLATE to obtain the proper treatment response. The tablet is marked with separation lines (scored lines) and may be broken at these scored lines to provide any of the following doses.</p>
<p class="Bold">150 mg treatment (take entire tablet)</p>
<p><img alt="150mg treatment" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=115f1010-882f-11e3-baa7-0800200c9a66&amp;name=acticlate-02.jpg"></p>
<p class="Bold">100 mg treatment (take two-thirds of the tablet or two 50 mg tablet segments)</p>
<p><img alt="100mg treatment" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=115f1010-882f-11e3-baa7-0800200c9a66&amp;name=acticlate-03.jpg"></p>
<p class="Bold">50 mg treatment (take one-third of the tablet)</p>
<p><img alt="50mg treatment" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=115f1010-882f-11e3-baa7-0800200c9a66&amp;name=acticlate-04.jpg"></p>
<p>To break the tablet, hold the tablet between your thumbs and index fingers close to the appropriate score line.  Then, apply enough pressure to snap the tablet segments apart (do not use segments that do not break along the score line).</p>
<p class="Bold">FDA-Approved Patient Labeling</p>
<p class="Bold">ACTICLATE<span class="Sup">™</span> Tablets</p>
<p class="Bold">Instructions for Breaking the 150 mg Tablet</p>
<p>Your doctor may find it necessary to adjust your dosage of ACTICLATE to obtain the proper treatment response. The tablet is marked with separation lines (scored lines) and may be broken at these scored lines to provide any of the following doses.</p>
<p class="Bold">150 mg treatment (take entire tablet)</p>
<p><img alt="150mg treatment (entire tablet)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=115f1010-882f-11e3-baa7-0800200c9a66&amp;name=acticlate-05.jpg"></p>
<p class="Bold">100 mg treatment (take two-thirds of the tablet or two 50 mg tablet segments)</p>
<p><img alt="100mg treatment (two-third tablet)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=115f1010-882f-11e3-baa7-0800200c9a66&amp;name=acticlate-06.jpg"></p>
<p class="Bold">50 mg treatment (take one-third of the tablet)</p>
<p><img alt="50mg treatment (one-third)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=115f1010-882f-11e3-baa7-0800200c9a66&amp;name=acticlate-07.jpg"></p>
<p>To break the tablet, hold the tablet between your thumbs and index fingers close to the appropriate score line.  Then, apply enough pressure to snap the tablet segments apart (do not use segments that do not break along the score line).</p>
<p class="Bold">Revised:  07/2014</p>
<p class="Bold">Rx only</p>
<p>AQUA PHARMACEUTICALS an Almirall company</p>
<p>Manufactured by Catalent Pharma Solutions, Winchester, KY 40391<br>
									For Aqua Pharmaceuticals, an Almirall Company West Chester, PA<br> 19380
								</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ABPDP03"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - NDC - 16110-501-01 75 mg Tablet 60-count Bottle</span></p>
<p><img alt="75 mg Tablet 60-count Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=115f1010-882f-11e3-baa7-0800200c9a66&amp;name=acticlate-08.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ABPDP06"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - NDC - 16110-502-01 150 mg Tablet 60-count Bottle</span></p>
<p><img alt="150 mg Tablet 60-count Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=115f1010-882f-11e3-baa7-0800200c9a66&amp;name=acticlate-09.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACTICLATE 		
					</strong><br><span class="contentTableReg">doxycycline hyclate tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16110-501</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOXYCYCLINE HYCLATE</strong> (DOXYCYCLINE ANHYDROUS) </td>
<td class="formItem">DOXYCYCLINE ANHYDROUS</td>
<td class="formItem">75 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (teal) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">75;AQ101</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16110-501-01</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA205931</td>
<td class="formItem">07/28/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACTICLATE 		
					</strong><br><span class="contentTableReg">doxycycline hyclate tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16110-502</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOXYCYCLINE HYCLATE</strong> (DOXYCYCLINE ANHYDROUS) </td>
<td class="formItem">DOXYCYCLINE ANHYDROUS</td>
<td class="formItem">150 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN (mossy green) </td>
<td class="formLabel">Score</td>
<td class="formItem">3 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">A;A;A</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16110-502-01</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA205931</td>
<td class="formItem">07/28/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Aqua Pharmaceuticals
							(605425912)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Catalent Pharma Solutions, LLC</td>
<td class="formItem"></td>
<td class="formItem">829672745</td>
<td class="formItem">MANUFACTURE(16110-501, 16110-502)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>50efb530-1430-11e4-8c21-0800200c9a66</div>
<div>Set id: 115f1010-882f-11e3-baa7-0800200c9a66</div>
<div>Version: 2</div>
<div>Effective Time: 20140725</div>
</div>
</div> <div class="DistributorName">Aqua Pharmaceuticals</div></p>
</body></html>
